Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo ...
Novo Nordisk Completes DKK 2.4 Billion Share Buyback
Novo Nordisk (NVO) has released an update. Novo Nordisk has successfully concluded a share repurchase program initiated on August 7, 2024, ...
Benzinga.com8h
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk stock faces bearish technicals, but analysts forecast nearly 46% upside. Novo inks $285 million Ascendis deal, ...
CBS News on MSN1d
Novo Nordisk's obesity-fighting drugs are fattening Denmark's economy while shrinking other sectors
Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...
Ascendis Pharma’s Strategic Partnership with Novo Nordisk Signals Strong Buy Rating Amid Growing Obesity Market
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ascendis Pharma (ASND – Research ...
With Novo Nordisk success, is there a "Nokia risk" for Denmark?
This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular ...
Ozempic, Wegovy sales inject wealth into Novo Nordisk home country of Denmark
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss medicine ...
Outsourcing-pharma6h
Novo Nordisk’s semaglutide shows additional cardiovascular benefits in overweight patients
Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and ...
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
Novo Nordisk ( NVO, Financials) entered an exclusive agreement with Ascendis Pharma ( ASND, Financials) to license Ascendis's TransCon technology platform for developing novel treatments targeting ...
Ascendis Pharma and Novo Nordisk Join Forces
Ascendis Pharma (ASND) has released an update. Ascendis Pharma has entered a collaboration with Novo Nordisk to license its ...
Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview
Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...